Advanced

Cost-utility analysis of adjuvant therapies for breast cancer in iran

Bastani, Peivand and Ahmad Kiadaliri, Aliasghar LU (2012) In International Journal of Technology Assessment in Health Care 28(2). p.110-114
Abstract
Objectives: The aim of this study was to evaluate the cost-utility of Docetaxel with doxorubicin and cyclophosphamide (TAC) and 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) in node-positive breast cancer patients in the south of Iran. Methods: A double blind study was done on a cohort of 100 patients suffering from breast cancer with node-positive over 8 months in the radiotherapy center of Namazi hospital, Shiraz-Iran. Health-related quality of life was assessed using questionnaire (QLQ-C30) from European Organization for Research and Treatment of Cancer (EORTC). QLQ-C30 scale scores were mapped to 15D and EuroQol 5D utilities to measure the quality-adjusted life-years (QALYs). Third party payer point of view was applied to measure... (More)
Objectives: The aim of this study was to evaluate the cost-utility of Docetaxel with doxorubicin and cyclophosphamide (TAC) and 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) in node-positive breast cancer patients in the south of Iran. Methods: A double blind study was done on a cohort of 100 patients suffering from breast cancer with node-positive over 8 months in the radiotherapy center of Namazi hospital, Shiraz-Iran. Health-related quality of life was assessed using questionnaire (QLQ-C30) from European Organization for Research and Treatment of Cancer (EORTC). QLQ-C30 scale scores were mapped to 15D and EuroQol 5D utilities to measure the quality-adjusted life-years (QALYs). Third party payer point of view was applied to measure and value the cost of treatments. Cost data were extracted from hospital and health insurance organizations. Robustness of the results was checked through a two way sensitivity analysis. Results: TAC was associated with higher deterioration in HRQoL during treatment and higher improvements over 4 months follow-up. On average, the cost of treatment per patient in TAC was 15 times higher than FAC (p < .001). In overall, TA( was resulted in lower QALYs and higher cost over study period.. Conclusions: FAC was a dominant option versus TAC in short-term. The higher improvement in HRQol. over follow-up in TAC may not compensate the more intensive deterioration caused during treatment in short-term. The short time horizon of study may limit the generalizability of our findings and, hence, there is a need to conduct long-term economic evaluation studies whenever data is available to inform decision making. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Cost-utility, Quality-adjusted life-years, Breast Cancer, Iran
in
International Journal of Technology Assessment in Health Care
volume
28
issue
2
pages
110 - 114
publisher
Cambridge
external identifiers
  • wos:000303369500004
  • scopus:84860780338
ISSN
1471-6348
DOI
10.1017/S0266462312000049
language
English
LU publication?
yes
id
3d040dde-b4bf-4c2b-9cf7-89b3cebf502c (old id 2561842)
date added to LUP
2012-06-01 08:46:21
date last changed
2017-01-01 03:41:15
@article{3d040dde-b4bf-4c2b-9cf7-89b3cebf502c,
  abstract     = {Objectives: The aim of this study was to evaluate the cost-utility of Docetaxel with doxorubicin and cyclophosphamide (TAC) and 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) in node-positive breast cancer patients in the south of Iran. Methods: A double blind study was done on a cohort of 100 patients suffering from breast cancer with node-positive over 8 months in the radiotherapy center of Namazi hospital, Shiraz-Iran. Health-related quality of life was assessed using questionnaire (QLQ-C30) from European Organization for Research and Treatment of Cancer (EORTC). QLQ-C30 scale scores were mapped to 15D and EuroQol 5D utilities to measure the quality-adjusted life-years (QALYs). Third party payer point of view was applied to measure and value the cost of treatments. Cost data were extracted from hospital and health insurance organizations. Robustness of the results was checked through a two way sensitivity analysis. Results: TAC was associated with higher deterioration in HRQoL during treatment and higher improvements over 4 months follow-up. On average, the cost of treatment per patient in TAC was 15 times higher than FAC (p &lt; .001). In overall, TA( was resulted in lower QALYs and higher cost over study period.. Conclusions: FAC was a dominant option versus TAC in short-term. The higher improvement in HRQol. over follow-up in TAC may not compensate the more intensive deterioration caused during treatment in short-term. The short time horizon of study may limit the generalizability of our findings and, hence, there is a need to conduct long-term economic evaluation studies whenever data is available to inform decision making.},
  author       = {Bastani, Peivand and Ahmad Kiadaliri, Aliasghar},
  issn         = {1471-6348},
  keyword      = {Cost-utility,Quality-adjusted life-years,Breast Cancer,Iran},
  language     = {eng},
  number       = {2},
  pages        = {110--114},
  publisher    = {Cambridge},
  series       = {International Journal of Technology Assessment in Health Care},
  title        = {Cost-utility analysis of adjuvant therapies for breast cancer in iran},
  url          = {http://dx.doi.org/10.1017/S0266462312000049},
  volume       = {28},
  year         = {2012},
}